Advice
in the absence of a submission from the holder of the marketing authorisation:
clostridium botulinum neurotoxin type A (Xeomin®) is not recommended for use within NHSScotland.
Indication under review: focal spasticity of the lower limb affecting the ankle joint.
The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.
Download detailed advice234KB (PDF)
Medicine details
- Medicine name:
- clostridium botulinum neurotoxin type A (Xeomin)
- SMC ID:
- SMC2680
- Indication:
Focal spasticity of the lower limb affecting the ankle joint.
- Pharmaceutical company
- Merz Pharma UK Ltd
- BNF chapter
- Central nervous system
- Submission type
- Non submission
- Status
- Not recommended
- Date advice published
- 10 June 2024